Literature DB >> 16737802

Generalized anxiety disorder: A comorbid disease.

David Nutt1, Spilos Argyropoulos, Sean Hood, John Potokar.   

Abstract

Generalized anxiety disorder (GAD) frequently occurs comorbidly with other conditions, including depression and somatic complaints. Comorbid GAD sufferers have increased psychologic and social impairment, request additional treatment, and have an extended course and poorer outcome than those with GAD alone; therapy should alleviate both the psychic and somatic symptoms of GAD without negatively affecting the comorbid condition. The ideal treatment would provide relief from both GAD and the comorbid condition, reducing the need for polypharmacy. Physicians need suitable tools to assist them in the detection and monitoring of GAD patients-the GADI, a new, self-rating scale, may meet this requirement. Clinical data have shown that various neurobiologic irregularities (e.g., in the GABA and serotonin systems) are associated with the development of anxiety. Prescribing physicians must take into account these abnormalities when choosing a drug. Effective diagnosis and treatment should improve patients' quality of life and their prognosis for recovery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16737802     DOI: 10.1016/j.euroneuro.2006.04.003

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  17 in total

1.  Distribution and quantitative detection of GABAA receptor in Carassius auratus gibelio.

Authors:  Jiming Ruan; Kun Hu; Haixin Zhang; Yi Wang; Ailing Zhou; Yini Zhao; Xianle Yang
Journal:  Fish Physiol Biochem       Date:  2014-04-01       Impact factor: 2.794

Review 2.  A review of neuroimaging studies in generalized anxiety disorder: "So where do we stand?"

Authors:  Bastiaan Goossen; Jeffrey van der Starre; Colin van der Heiden
Journal:  J Neural Transm (Vienna)       Date:  2019-06-20       Impact factor: 3.575

3.  The burden of generalized anxiety disorder in Canada.

Authors:  Louise Pelletier; Siobhan O'Donnell; Louise McRae; Jean Grenier
Journal:  Health Promot Chronic Dis Prev Can       Date:  2017-02       Impact factor: 3.240

4.  Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.

Authors:  Jonathan R T Davidson; Douglas E Feltner; Ashish Dugar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 5.  The impact of medication on health-related quality of life in patients with generalized anxiety disorder.

Authors:  Hilary Wilson; Sally Mannix; Hafiz Oko-osi; Dennis A Revicki
Journal:  CNS Drugs       Date:  2015-01       Impact factor: 5.749

Review 6.  Current considerations in the treatment of generalized anxiety disorder.

Authors:  Martin A Katzman
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

7.  Attention modification program in individuals with generalized anxiety disorder.

Authors:  Nader Amir; Courtney Beard; Michelle Burns; Jessica Bomyea
Journal:  J Abnorm Psychol       Date:  2009-02

8.  Disentangling emotion processes in borderline personality disorder: physiological and self-reported assessment of biological vulnerability, baseline intensity, and reactivity to emotionally evocative stimuli.

Authors:  Janice R Kuo; Marsha M Linehan
Journal:  J Abnorm Psychol       Date:  2009-08

Review 9.  Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety.

Authors:  R E Nordquist; T Steckler; J G Wettstein; C Mackie; W Spooren
Journal:  Psychopharmacology (Berl)       Date:  2008-03-06       Impact factor: 4.530

10.  The frequency of depression and the comorbidity of psychotic disorders at day hospital of psychiatric clinic, clinical center of sarajevo university.

Authors:  Alem Cesir; Ifeta Licanin; Saida Fisekovic
Journal:  Mater Sociomed       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.